Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Current Assets (2016 - 2025)

Historic Current Assets for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to $738.7 million.

  • Viking Therapeutics' Current Assets fell 2113.34% to $738.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $738.7 million, marking a year-over-year decrease of 2113.34%. This contributed to the annual value of $907.2 million for FY2024, which is 14704.64% up from last year.
  • As of Q3 2025, Viking Therapeutics' Current Assets stood at $738.7 million, which was down 2113.34% from $827.0 million recorded in Q2 2025.
  • Viking Therapeutics' 5-year Current Assets high stood at $966.3 million for Q1 2024, and its period low was $149.5 million during Q1 2023.
  • For the 5-year period, Viking Therapeutics' Current Assets averaged around $479.6 million, with its median value being $367.2 million (2023).
  • In the last 5 years, Viking Therapeutics' Current Assets plummeted by 2636.78% in 2022 and then skyrocketed by 54651.63% in 2024.
  • Quarter analysis of 5 years shows Viking Therapeutics' Current Assets stood at $210.5 million in 2021, then fell by 20.66% to $167.0 million in 2022, then surged by 119.84% to $367.2 million in 2023, then surged by 147.05% to $907.2 million in 2024, then dropped by 18.57% to $738.7 million in 2025.
  • Its Current Assets stands at $738.7 million for Q3 2025, versus $827.0 million for Q2 2025 and $866.0 million for Q1 2025.